Zamzami N, Susin S A, Marchetti P, Hirsch T, Gómez-Monterrey I, Castedo M, Kroemer G
Centre National de la Recherche Scientifique (CNRS)-UPR420, Villejuif, France.
J Exp Med. 1996 Apr 1;183(4):1533-44. doi: 10.1084/jem.183.4.1533.
Anucleate cells can be induced to undergo programmed cell death (PCD), indicating the existence of a cytoplasmic PCD pathway that functions independently from the nucleus. Cytoplasmic structures including mitochondria have been shown to participate in the control of apoptotic nuclear disintegration. Before cells exhibit common signs of nuclear apoptosis (chromatin condensation and endonuclease-mediated DNA fragmentation), they undergo a reduction of the mitochondrial transmembrane potential (delta psi m) that may be due to the opening of mitochondrial permeability transition (PT) pores. Here, we present direct evidence indicating that mitochondrial PT constitutes a critical early event of the apoptotic process. In a cell-free system combining purified mitochondria and nuclei, mitochondria undergoing PT suffice to induce chromatin condensation and DNA fragmentation. Induction of PT by pharmacological agents augments the apoptosis-inducing potential of mitochondria. In contrast, prevention of PT by pharmacological agents impedes nuclear apoptosis, both in vitro and in vivo. Mitochondria from hepatocytes or lymphoid cells undergoing apoptosis, but not those from normal cells, induce disintegration of isolated Hela nuclei. A specific ligand of the mitochondrial adenine nucleotide translocator (ANT), bongkreik acid, inhibits PT and reduces apoptosis induction by mitochondria in a cell-free system. Moreover, it inhibits the induction of apoptosis in intact cells. Several pieces of evidence suggest that the proto-oncogene product Bcl-2 inhibits apoptosis by preventing mitochondrial PT. First, to inhibit nuclear apoptosis, Bcl-2 must be localized in mitochondrial but not nuclear membranes. Second, transfection-enforced hyperexpression of Bcl-2 directly abolishes the induction of mitochondrial PT in response to a protonophore, a pro-oxidant, as well as to the ANT ligand atractyloside, correlating with its apoptosis-inhibitory effect. In conclusion, mitochondrial PT appears to be a critical step of the apoptotic cascade.
无核细胞可被诱导发生程序性细胞死亡(PCD),这表明存在一条独立于细胞核发挥作用的细胞质PCD途径。包括线粒体在内的细胞质结构已被证明参与凋亡性核解体的控制。在细胞表现出核凋亡的常见迹象(染色质凝聚和核酸内切酶介导的DNA片段化)之前,它们会经历线粒体跨膜电位(Δψm)的降低,这可能是由于线粒体通透性转换(PT)孔的开放所致。在此,我们提供直接证据表明线粒体PT是凋亡过程中的一个关键早期事件。在一个将纯化的线粒体和细胞核结合的无细胞系统中,发生PT的线粒体足以诱导染色质凝聚和DNA片段化。药物诱导PT会增强线粒体的凋亡诱导潜力。相反,药物预防PT会在体外和体内阻碍核凋亡。来自正在凋亡的肝细胞或淋巴细胞的线粒体,而不是来自正常细胞的线粒体,可诱导分离的HeLa细胞核解体。线粒体腺嘌呤核苷酸转位酶(ANT)的一种特异性配体,即邦克酸,可抑制PT并降低无细胞系统中线粒体诱导的凋亡。此外,它还抑制完整细胞中的凋亡诱导。几条证据表明原癌基因产物Bcl-2通过阻止线粒体PT来抑制凋亡。首先,为了抑制核凋亡,Bcl-2必须定位于线粒体膜而非核膜。其次,转染强制过表达的Bcl-2可直接消除对质子载体、促氧化剂以及ANT配体苍术苷的反应中线粒体PT的诱导,这与其凋亡抑制作用相关。总之,线粒体PT似乎是凋亡级联反应中的关键步骤。